Opendata, web and dolomites

EIS SIGNED

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EIS project word cloud

Explore the words cloud of the EIS project. It provides you a very rough idea of what is the project "EIS" about.

market    platform    obtain    severe    feasibility    pressure    worldwide    treatment    amd    opportunity    debilitating    utilizing    performed    lasting    retinitis    iop    ga    reduces    macular    close    retina    ivts    strategy    innovative    longer    impairments    causes    therapeutic    vessels    dr    risk    ensures    disease    innovation    mscs    plan    drafted    marketing    ivt    suffering    glaucoma    cataract    first    retinal    clinical    area    hbm    chain    transplantation    bone    blood    rp    regard    registered    life    optimal    visual    drug    photoreceptor    million    patients    degenerative    choroidal    goto    office    atrophy    escalation    injections    perform    billion    degeneration    everads    treatments    human    cell    minimally    dosage    fact    geographic    stromal    multiple    80    people    safe    cells    initiated    age    setting    adult    leaving    techniques    pigmentosa    marrow    supply    combination    intravitreal    injection    matrix    standard    daily    treat    license    device    effect    subretinal    invasive    mesenchymal    organ    trials    excellent    blindness    approximately    eis    consequence    ocular   

Project "EIS" data sheet

The following table provides information about the project.

Coordinator
EVERADS THERAPY LTD 

Organization address
address: 27 HABARZEL STREET MIGDALEI ORR BUILDING A 5TH FLO
city: TEL AVIV
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERADS THERAPY LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Retinal degenerative disease is a debilitating condition with a major impact on daily life. This includes Geographic Atrophy(GA) - as a consequence of age-related macular degeneration (AMD) - and advanced Retinitis Pigmentosa (RP) - all characterized by photoreceptor loss. In fact, they are the main causes of registered blindness. In this regard, there are no currently effective treatments for patients suffering from GA a and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them. Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). Unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunity. The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections. During the feasibility assessment, a goto market strategy and a supply chain will be established, and further development plan will be drafted. During the phase 2 of innovation project, Everads will perform further product development and cell distribution and dosage escalation activities. Multiple first in human clinical trials will be initiated to obtain marketing license as a drug-device combination product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MealHero (2019)

Automated cooking for tasty and healthy meals in a convenient way

Read More  

SPANAR (2019)

Safe Perception And Navigation for Autonomous Robots

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More